Trial Profile
Telmisartan Effectiveness on Left Ventricular MAss Reduction (TELMAR) as Assessed by MRI, in Patients With Mild to Moderate Hypertension - a Prospective, Randomised, Double-blind Comparison of Telmisartan 80 mg Oral, Once Daily, to Metoprolol Succinate 95 mg Oral, Once Daily, Over a Period of 6 Months
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 23 Sep 2014
Price :
$35
*
At a glance
- Drugs Telmisartan (Primary) ; Metoprolol succinate
- Indications Essential hypertension; Left ventricular hypertrophy
- Focus Therapeutic Use
- Acronyms TELMAR
- Sponsors Boehringer Ingelheim
- 23 Sep 2014 New trial record